Stanley Lapidus

Stanley Lapidus discloses dealings in 2 companies, chiefly T2 Biosystems, Inc. and Lucid Diagnostics Inc. Over a trading history stretching from 6 June 2017 to 20 February 2026, the count stands at 13 filings.

Every open-market trade on record is a sale: 7 sales worth €39k. Other entries cover 2 share grants and 4 option exercises.

Most recently, on 24 February 2026, the filings show a share grant in Lucid Diagnostics Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.